Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pralsetinib→

Pralsetinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2097132-93-7
PubChem CID
129073603
Molecular formula
C27H32FN9O2
Molecular weight
533.6 g/mol
Drug class
Kinase Inhibitor
Mechanism of action
Rearranged during Transfection (RET) Inhibitors
Indications / reported uses
  • Carcinoma, Non-Small-Cell Lung

Identification source: PubChem record (CID 129073603). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pralsetinib Environmental Risk Assessment (ERA) (the Pralsetinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.